Abstract

In 2006, the induced pluripotent stem cell (iPSC) was presented to the world, paving the way for the development of a magnitude of novel therapeutic alternatives, addressing a diverse range of diseases. However, despite the immense cell therapy potential, relatively few clinical trials evaluating iPSC-technology have actually translated into interventional, clinically applied treatment regimens. Herein, our aim was to determine trends in globally conducted clinical trials involving iPSCs. Data were derived both from well-known registries recording clinical trials from across the globe, and databases from individual countries. Comparisons were firstly drawn between observational and interventional studies before the latter was further analyzed in terms of therapeutic and nontherapeutic trials. Our main observations included global distribution, purpose, target size, and types of disorder relevant to evaluated trials. In terms of nontherapeutic trials, the USA conducted the majority, a large average number of participants-187-was included in the trials, and studies on circulatory system disorders comprised a slightly higher proportion of total studies. Conversely, Japan was the frontrunner in terms of conducting therapeutic trials, and the average number of participants was much lower, at roughly 29. Disorders of the circulatory, as well as nervous and visual systems, were all studied in equal measure. This review highlights the impact that iPSC-based cell therapies can have, should development thereof gain more traction. We lastly considered a few companies that are actively utilizing iPSCs in the development of therapies for various diseases, for whom the global trends in clinical trials could become increasingly important.

Keywords: Allogeneic; Autologous; Cell therapy; Clinical trials; Induced pluripotent stem cells; Interventional; Nontherapeutic; Therapeutic.

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests. Y.N. are employee at YiPSCELL, Inc., and J.H.J. is the employer. J.H.J. is the founder of YiPSCELL. Inc. and also a MD and professor at the Seoul St. Mary’s hospital, Catholic University of Korea.

Figures

Fig. 1 

Classification of global clinical trials…

Fig. 2 

Distribution of clinical trials involving…

Fig. 3 

Distribution of therapeutic clinical trials…

Fig. 4 

Companies that aim to develop…

Similar articles

• Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis.

  Deinsberger J, Reisinger D, Weber B.NPJ Regen Med. 2020 Sep 11;5:15. doi: 10.1038/s41536-020-00100-4. eCollection 2020.PMID: 32983575 Free PMC article.

• Autologous Induced Pluripotent Stem Cell-Based Cell Therapies: Promise, Progress, and Challenges.

  Madrid M, Sumen C, Aivio S, Saklayen N.Curr Protoc. 2021 Mar;1(3):e88. doi: 10.1002/cpz1.88.PMID: 33725407 Review.

• The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.

  Scheiner ZS, Talib S, Feigal EG.J Biol Chem. 2014 Feb 21;289(8):4571-7. doi: 10.1074/jbc.R113.509588. Epub 2013 Dec 20.PMID: 24362036 Free PMC article. Review.

• Clinical applications of pluripotent stem cells and their derivatives: current status and future perspectives.

  Pendse S, Vaidya A, Kale V.Regen Med. 2022 Sep;17(9):677-690. doi: 10.2217/rme-2022-0045. Epub 2022 Jun 15.PMID: 35703035 Review.

• Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.

  Sadeqi Nezhad M, Abdollahpour-Alitappeh M, Rezaei B, Yazdanifar M, Seifalian AM.Pharm Res. 2021 Jun;38(6):931-945. doi: 10.1007/s11095-021-03067-z. Epub 2021 Jun 10.PMID: 34114161 Review.

Cited by

• Neural stem cells derived from α-synuclein-knockdown iPS cells alleviate Parkinson's disease.

  Wang CH, Lin GC, Fu RH, Huang YC, Chen SY, Lin SZ, Harn HJ, Shyu WC, Huang YF, Jeng LB, Liu SP.Cell Death Discov. 2024 Sep 17;10(1):407. doi: 10.1038/s41420-024-02176-z.PMID: 39285205 Free PMC article.

• Submission to Stem Cells Reviews and Reports.

  Escribá R, Beksac M, Bennaceur-Griscelli A, Glover JC, Koskela S, Latsoudis H, Querol S, Alvarez-Palomo B.Stem Cell Rev Rep. 2024 Sep 14. doi: 10.1007/s12015-024-10783-7. Online ahead of print.PMID: 39276260 Review.

• Tissue engineering and regenerative medicine approaches in colorectal surgery.

  Mainali BB, Yoo JJ, Ladd MR.Ann Coloproctol. 2024 Aug;40(4):336-349. doi: 10.3393/ac.2024.00437.0062. Epub 2024 Aug 30.PMID: 39228197 Free PMC article. Review.

• The impact of repeated temperature cycling on cryopreserved human iPSC viability stems from cytochrome redox state changes.

  Okuda J, Watanabe N, Nakamura T, Mizushima K, Xi H, Kumamoto Y, Fujita K, Kino-Oka M.Front Bioeng Biotechnol. 2024 Jul 30;12:1443795. doi: 10.3389/fbioe.2024.1443795. eCollection 2024.PMID: 39139293 Free PMC article.

• Novel Technologies to Address the Lower Motor Neuron Injury and Augment Reconstruction in Spinal Cord Injury.

  Bazarek SF, Krenn MJ, Shah SB, Mandeville RM, Brown JM.Cells. 2024 Jul 22;13(14):1231. doi: 10.3390/cells13141231.PMID: 39056812 Free PMC article. Review.

References

1. 1. Nam, Y., Rim, Y. A., & Ju, J. H. (2017). Chondrogenic pellet formation from cord blood-derived induced pluripotent stem cells. Journal of Visualized Experiments, (124). - PMC - PubMed
2. 1. Nam Y, et al. Cord blood cell-derived iPSCs as a new candidate for chondrogenic differentiation and cartilage regeneration. Stem Cell Research & Therapy. 2017;8(1):16. doi: 10.1186/s13287-017-0477-6. - DOI - PMC - PubMed
3. 1. Nam Y, et al. Current therapeutic strategies for stem cell-based cartilage regeneration. Stem Cells Int. 2018;2018:8490489. doi: 10.1155/2018/8490489. - DOI - PMC - PubMed
4. 1. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell. 2007;1(1):39–49. doi: 10.1016/j.stem.2007.05.012. - DOI - PubMed
5. 1. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiation research. 1961;14(2):213–222. doi: 10.2307/3570892. - DOI - PubMed

Publication types

• Research Support, Non-U.S. Gov't

• Review